

# A randomised study of 'bluelight' hexyl aminolevulinic acid (HAL) photodynamic assisted resection of bladder tumours versus conventional 'whitelight' transurethral resection of newly diagnosed bladder tumours comparing rates of tumour recurrence over one year - a Phase IV trial

<b>Submission date</b> 25/07/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 02/09/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 19/11/2015	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Mr Timothy O'Brien

### Contact details

Dept. Urology  
1st Floor Thomas Guy House  
Guy's Hospital  
St Thomas' Street  
London  
United Kingdom  
SE1 9RT  
+44 (0)207 1886796  
tim.obrien@gstt.nhs.uk

# Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

04/QO603/42

## Study information

### Scientific Title

A randomised study of 'bluelight' hexyl aminolevulinic acid (HAL) photodynamic assisted resection of bladder tumours versus conventional 'whitelight' transurethral resection of newly diagnosed bladder tumours comparing rates of tumour recurrence over one year - a Phase IV trial

### Study objectives

The aim is to determine if photodynamic assisted resection can reduce the recurrence rate of tumour at one year when compared with the control group. The primary endpoint is the diagnosis of recurrent tumour at 3 months or 12 months on check cystoscopy.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Not provided at time of registration

### Study design

Randomised controlled trial

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Hospital

### Study type(s)

Treatment

### Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

### Health condition(s) or problem(s) studied

Bladder cancer

## **Interventions**

Intervention: Pre-operative intravesical instillation of solution of hexylaminolevulinic acid (HAL) - photodynamic 'bluelight' assisted resection of bladder tumours

Control: Conventional 'whitelight' transurethral resection

## **Intervention Type**

Drug

## **Phase**

Phase IV

## **Drug/device/biological/vaccine name(s)**

Hexyl aminolevulinic acid (HAL)

## **Primary outcome measure**

Recurrence rates of bladder tumour at 3 months and 12 months post surgery

## **Secondary outcome measures**

Analysis of histology

## **Overall study start date**

01/02/2005

## **Completion date**

01/02/2007

# **Eligibility**

## **Key inclusion criteria**

1. New diagnosis of bladder tumour - the study is designed to reduce recurrence rates in newly diagnosed cases of bladder tumours
2. Superficial disease - the study will address the recurrence rates in superficial bladder cancer
3. No history of previous bladder surgery - previous surgical procedures to the bladder may cause artifactual changes when using 'blue light' cystoscopy
4. Life expectancy of at least 1-year - study duration will be for 1-year

## **Participant type(s)**

Patient

## **Age group**

Adult

## **Sex**

Both

## **Target number of participants**

200 (100 in each group)

## **Key exclusion criteria**

1. Previous bladder tumour or coexisting/previous upper tract disease - the study is designed to reduce recurrence rates in newly diagnosed cases of bladder tumours
2. Muscle invasive disease - the study will address the recurrence rates in superficial bladder cancer
3. Previous bladder surgery -previous surgical procedures to the bladder may cause artifactual changes when using 'blue light' cystoscopy

**Date of first enrolment**

01/02/2005

**Date of final enrolment**

01/02/2007

## **Locations**

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

**Guy's Hospital**

London

United Kingdom

SE1 9RT

## **Sponsor information**

**Organisation**

Guy's Hospital - Research and Development Department (UK)

**Sponsor details**

Ground Floor

West Wing Counting House

Guy's Hospital

St Thomas' Street

London

England

United Kingdom

SE1 9RT

**Sponsor type**

Hospital/treatment centre

**ROR**

## Funder(s)

### Funder type

Charity

### Funder Name

Guy's and St Thomas' Charity (UK)

### Alternative Name(s)

Guy's and St Thomas' Charity, Guy's and St Thomas' Foundation, GSTTFoundation

### Funding Body Type

Private sector organisation

### Funding Body Subtype

Trusts, charities, foundations (both public and private)

### Location

United Kingdom

## Results and Publications

### Publication and dissemination plan

Not provided at time of registration

### Intention to publish date

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/12/2013		Yes	No